The pharmaceutical industry has experienced a remarkable advancement in diabetes management with the arrival of copyright. This revolutionary medication, designated as a glucagon-like peptide-1 (GLP-1) receptor agonist, offers a novel approach to managing blood sugar levels in individuals with type